Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 19/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.44 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.41 |
| ▸ | CALCA | P06881 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13303229 | 0.94 | CALCRL (0.49) | CALCRLCYP3A4CALCA | |
| SCHEMBL3282603 | 0.93 | CALCRL (0.46) | CALCRLCYP3A4RAMP1 | |
| SCHEMBL3278156 | 0.87 | CALCRL (0.51) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL3342254 | 0.87 | CALCRL (0.45) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL3278144 | 0.87 | CALCRL (0.51) | CALCRLCYP3A4RAMP1CALCA | |
| SCHEMBL3282456 | 0.85 | CALCRL (0.52) | CALCRLCYP3A4 | |
| SCHEMBL6226167 | 0.85 | CALCRL (0.52) | CALCRLCYP3A4 | |
| SCHEMBL3278960 | 0.85 | CALCRL (0.51) | CALCRLCYP3A4RAMP1 | |
| SCHEMBL6224254 | 0.81 | CALCRL (0.45) | CALCRLCYP3A4RAMP1 | |
| SCHEMBL3282820 | 0.79 | CALCRL (0.44) | CALCRLCYP3A4RAMP1CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152171-A1 | CGRP Antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-20100152171-A1 | CGRP Antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-7700589-B2 | CGRP antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-04-20 | — | — | US | disclosed |
| US-7700589-B2 | CGRP antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-04-20 | — | — | US | disclosed |
| US-20070244099-A1 | CGRP Antagonists | RUDOLF KLAUS | 2007-10-18 | — | — | US | disclosed |
| US-20070244099-A1 | CGRP Antagonists | RUDOLF KLAUS | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244099-A1 | CGRP Antagonists | CALCRL, OPRL1, CALCA | CALCRL 1/4885CYP3A4 2631/4885RAMP1 36/4885 |
| US-20100152171-A1 | CGRP Antagonists | CALCRL, OPRL1, CALCA | CALCRL 1/4885CYP3A4 2631/4885RAMP1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.